Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH. Budget impact analysis of tapentadol
extended-release (ER) for the treatment of moderate to severe chronic
pain. Clin Ther 2013;35:659-72.
Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R. Impact of solifenacin on quality of life,
medical care use, work productivity and health utility in the elderly: an
exploratory subgroup analysis. Am J
Geriatric Pharmacother 2009;7:373-382.
Noe L, Neil N, Ogden K, Turini M.
Medical foods and foods for special medical purposes. Value Health 2009;12(7):A255 (Abstract).
Spalding J, Exuzides A, Colby C, Neil N, Noe L. Management of primary
atrial fibrillation (AF): patient
characteristics and hospital care setting.
Value Health 2009;12(3):A153 (Abstract).
Spalding J, Exuzides A, Colby C, Neil N, Noe L. Inpatient resource use among patients treated
for primary atrial fibrillation (AF):
role of clinical factors and choice of initial conversion therapy. Value
Health 2009;12(3):A153 (Abstract).
Spalding JR, Exuzides A, Adams S, Colby C, Noe L. Inpatient resource
use associated with the treatment of secondary atrial fibrillation. Value
Health 2008;11(6):A399 (Abstract).
Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K,
Claus R, Andrews WT, Roach J. Comparison
of levalbuterol and racemic albuterol in hospitalized patients with acute
asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clin Ther 2008;30:Theme Issue.
Belz M, Spalding J, Exuzides A, Adams S, Colby C, Noe L, Neil N. Likelihood and cost of adverse events in
atrial fibrillation are associated with choice of acute conversion
therapy. Value Health 2008;11(3):A200
(Abstract).
Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource
utilization, work productivity and health utility in overactive bladder
patients switching from tolterodine ER.
Curr Med Res Opin 2008;24:1583-91.
Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella
MC. Reimbursement and economic factors
influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008;23:2365-73.
Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro
F. Economic evaluations of dialysis
treatment modalities. Health Policy
2008;86:163-180.
Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro
FT. Global economic evaluations of dialysis
treatment modalities. Value Health
2007;10(6):A317 (Abstract).
Hansen R, Seifeldin R, Noe
L. Medication adherence in post-transplant
immunosuppression: the economic impact of drug-regimen complexity. Value Health. 2007;10(6):A368 (Abstract).
Hansen R, Seifeldin R, Noe L.
Medication adherence in chronic disease: Issues in posttransplant
immunosupprestion. Transplant Proc
2007;Jun;39(5):1287-300.
Pasta D, Silva S, Noe LL, Claus R, Schaefer K, Andrews W, Roach J.
Quality-adjusted length of stay analysis of hospitalized patients with asthma
or COPD treated with Levalbuterol or Racemic Albuterol. Value Health
2007;10(3):A110.
Claus R, Noe LL, Pasta D, Schaefer K, Andrews W, Roach J.
Pharmacoeconomic outcomes of levalbuterol and racemic albuterol in hospitalized
patients requiring nebulization therapy (POLARIS). Value Health
2007;10(3):A110.
Noe LL, Marshall TS, Rasouliyan L, Runken MC, Zinner NR. Impact of
solifenacin on quality of life, medical care use, work productivity, and health
utility in the elderly. Value Health 2007;10(3):A108.
Neil N, Block S, Ogden K, Noe LL, Black L, Williamson TE. Modeling the
costs and outcomes of solifenacin vs. behavioral therapy or no therapy for
treatment of overactive bladder in primary care. Pharmacotherapy
2005;25(10):1490.
Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Application of an
algorithm for defining retrospective cohorts of colorectal cancer (CRC)
patients treated with different first-line chemotherapy regiments +/-
bevacizumab to administrative claims data. Value Health. 2005;8(6):A45.
Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Development of an
algorithm for the identification and classification of colorectal cancer (CRC)
patients according to first-line chemotherapy regiments +/- bevacizumab, and
initiation of second-line therapy using administrative claims. Value Health. 2005;8(6):A45.
Neil N, Lamm D, Ogden K, Noe LL, Peterson L, Mallick R. A simulation
model of the cost of treatment failure in patients hospitalized with
community-acquired pneumonia (CAP) in the US. Clin Microbiol Infect.
2005;11(Suppl 2):O59.
Noe LL, Sneeringer R, Patel B, Williamson T. The implications of poor
medication persistence with treatment for overactive bladder. Managed Care
Interface. 2004 Nov;54-60.
Becker RV, Noe LL, Chen DM, Williamson T. Evaluating the cost of
long-acting treatments for overactive bladder. Value Health. 2002;5(6):583.
Noe LL, Becker RV, Chen DM, Williamson T. A straightforward
cost-effectiveness analysis of long-acting treatments for overactive bladder:
Can it be this simple? Value Health. 2002;5(6):582-3.
Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model
comparing two long-acting treatments for overactive bladder. JMCP.
2002;8(5):343-52.
Hufford MR, Noe L.
Patient-Reported Outcomes: A Comparison of Two Data-Capture
Methods. Value in Health
2001;4(6):(Abstract).
Becker R, Noe L, Gore M, Chen D.
Using Level of Evidence Criteria in the Evaluation of Pharmacoeconomic
Results. Value in Health
2001;4(6):(Abstract).
Becker R, Noe L, Gore M, Chen D.
Incorporating Clinical Level-of-Evidence Criteria into a Breast Cancer
Treatment Model for Japan. Value in
Health 2001;4(6):(Abstract).
Becker R, Noe L, Gore M, Martino S.
A new approach to disease modeling with numerous comparators and
multiple decision trees. Value in Health
2001;4(2):189-190 (Abstract).
Noe L, Hankin CS. Health
outcomes of childhood attention-deficit/hyperactivity disorder (ADHD): Health
care use and work status of caregivers.
Value in Health 2001;4(2):142-143 (Abstract).
Becker RV, Noe L, Gore M, Martino S, Eiermann W, Namer M, Howell A,
Bianco A, Watanabe T. Disease modeling:
Developing the infrastructure for a comprehensive, multi-national, clinical and
economic breast cancer treatment model.
Value in Health 2001;4(2):93 (Abstract).
Noe L. Impact of
attention-deficit/hyperactivity disorder (ADHD) on healthcare use and work
status: A survey of caregivers. J
Managed Care Pharmacy 2001;7(2):133 (Abstract).
Kavanaugh A, Patel K, Bala M, Noe L.
Cost-effectiveness of infliximab in rheumatoid arthritis. Arthritis
Rheum 2000;43(9) Supplement: S144 (Abstract).
Noe L, Peeples P. Medical
resource consumption by patients with chronic and breakthrough pain. Value in Health 2000;3(2):84 (Abstract).
Noe LL, Becker RV, Gore M, Martino S, Eiermann W, Namer M, Howell A,
Bianco AR, Watanabe T, Chen DM. An
approach to designing a multi-national model for the current treatment of
breast cancer. Value in Health
2000;3(5):353 (Abstract).
